| P2093 | author name string | Louviaux I | |
| | Sculier JP | |
| | Paesmans M | |
| | Berghmans T | |
| | Mascaux C | |
| | Meert AP | |
| | Lalami Y | |
| | Luce S | |
| P2860 | cites work | An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma | Q28318141 |
| | Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. | Q31878746 |
| | Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma | Q33327891 |
| | Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study | Q33329809 |
| | Caelyx in malignant mesothelioma: a phase II EORTC study | Q33333558 |
| | Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study | Q33337004 |
| | Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group | Q33376559 |
| | Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. | Q33401558 |
| | A phase II study of pirarubicin in malignant pleural mesothelioma | Q33409204 |
| | Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis | Q71067270 |
| | A phase II study of m-AMSA in patients with malignant mesothelioma | Q71246811 |
| | Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party | Q71261838 |
| | Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients | Q71261893 |
| | Two dose levels of ifosfamide in malignant mesothelioma | Q71709257 |
| | Oral etoposide in the treatment of malignant mesothelioma. A phase II study | Q72109359 |
| | Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study | Q72325011 |
| | Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma | Q72387721 |
| | Phase II study of vinorelbine in patients with malignant pleural mesothelioma | Q73250833 |
| | Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force | Q73335125 |
| | Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group | Q74201928 |
| | Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma | Q74202142 |
| | Phase II study of intravenous Doxil in malignant pleural mesothelioma | Q74222595 |
| | A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma | Q74661222 |
| | Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study | Q77596987 |
| | Phase II trial of topotecan for the treatment of mesothelioma | Q77695228 |
| | Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors | Q77715500 |
| | Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile | Q77839280 |
| | Ifosfamide in malignant mesothelioma: a phase II study | Q77994612 |
| | Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma | Q78147639 |
| | The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent | Q78846264 |
| | A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma | Q33491455 |
| | Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study | Q33491606 |
| | Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a | Q33495644 |
| | Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. | Q33778099 |
| | Do authors of review articles use systematic methods to identify, assess and synthesize information? | Q34459675 |
| | High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study | Q35994031 |
| | Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group | Q36136075 |
| | High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma | Q36620561 |
| | Weekly high-dose cisplatin in malignant pleural mesothelioma | Q36738779 |
| | Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma | Q36792340 |
| | Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)--Mesothelioma Committee. | Q37697055 |
| | Chemotherapy in malignant pleural mesothelioma. A review. | Q38563914 |
| | Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma | Q39447961 |
| | Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma | Q39545682 |
| | A prospective study of detorubicin in malignant mesothelioma | Q39546869 |
| | Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients | Q40609271 |
| | A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma | Q40609339 |
| | Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study | Q40618320 |
| | Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma | Q40677236 |
| | Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. | Q40698568 |
| | Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma | Q40704782 |
| | Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma | Q40749578 |
| | Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study | Q40757753 |
| | High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. | Q40804584 |
| | Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. | Q40827609 |
| | Maintenance chemotherapy for small cell lung cancer: a critical review of the literature | Q40861064 |
| | Menogaril in the treatment of malignant mesothelioma: a phase II study | Q41616374 |
| | A review of chemotherapy trials for malignant mesothelioma | Q41687000 |
| | Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. | Q42543213 |
| | Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. | Q42549226 |
| | Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma | Q43634484 |
| | Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma | Q43793712 |
| | A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study | Q43997685 |
| | A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma | Q44664696 |
| | A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. | Q54257982 |
| | A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study | Q68039315 |
| | Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group | Q68101494 |
| | Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study | Q68126270 |
| | Phase II trial of carboplatin in the management of malignant mesothelioma | Q68926131 |
| | A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma | Q68927687 |
| | Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study | Q68929587 |
| | A phase II study of vincristine in malignant mesothelioma--a negative report | Q69627142 |
| | Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study | Q70176734 |
| | Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura | Q70202335 |
| | Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin | Q70582746 |
| | Effect of interferon-alpha 2a on malignant mesothelioma | Q70615554 |
| | Clinical aspects of malignant mesothelioma in Australia | Q70630512 |
| P433 | issue | 2 | |
| P921 | main subject | immunotherapy | Q1427096 |
| | meta-analysis | Q815382 |
| | chemotherapy | Q974135 |
| | systematic review | Q1504425 |
| P304 | page(s) | 111-121 | |
| P577 | publication date | 2002-11-01 | |
| P1433 | published in | Lung Cancer | Q641464 |
| P1476 | title | Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis | |
| P478 | volume | 38 | |